Cardiomyopathy, ischemic heart disease, and rheumatic heart disease are big issues for our local community. The early detection of cardiomyopathy can prevent the incidence of sudden cardiac death, and reversal of dilated cardiomyopathy is also possible in some cases. However, there is much about heart failure that is not known.
Mātai will follow high-risk patients in Gisborne using standard and advanced imaging. Our analysis will involve computational modelling and deep learning in conjunction with the collected data from patients. Through partnerships with a global network of experts, we will be well placed to investigate the utility of 4D flow imaging (which allows visualisation and quantification of blood flow), myocardial strain, and tissue mapping in the evaluation of heart disease. These methods have only recently become available, and we will be at the forefront of this new technology, which has great potential for assessing cardiac disease progression.
Using cloud-based imaging and cardiac modelling software based on MRI data, we will enable equal/greater access to expert cardiac care for those with high-risk of heart failure by providing automated software that helps clinicians in their diagnosis. Research in automated image acquisition, image acquisition speed, and motion correction; available to Matai through our partnerships, can make cardiac MRI available in sites without onsite expertise and for patients with reduced ability to lie still or hold their breath.
Image courtesy of John Axerio-Cilies, COO and founder of Arterys.